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Aims: Increased production of reactive oxygen species (ROS) in mitochondria, play an important role in
the cardiovascular system. Furthermore, oxidative metabolism of mitochondria comprised of biophoton
emissions, are linked to ROS and oxidative stress. In this review we investigated the association between
the ability of ClearViewTM system (ClearView) to indicate the presence or absence of cardiovascular
disease through mitochondria respiration as depicted through biophotonic emission.
Methods and results: One hundred and ninety-ﬁve out of the three hundred and ﬁfty-three human
subjects enrolled in this prospective, single site study had at least one cardiovascular related diagnosis.
Measurements with ClearView consisted of scanning all 10 ﬁngers twice. Images were captured through
the ClearView software and analyzed to produce a scale that indicates the presence or absence of car-
diovascular disease. The association of ClearView's ability to indicate the presence or absence of cardi-
ovascular disease with a physician's diagnosis was assessed using odds ratios (OR) and area under ROC
curve (AUC). Adjusting for age, OR of ClearView measurements conducted with capacitive barrier was
3.44 (95%CI: 2.13, 5.55) and the OR without the capacitive barrier was 2.15 (95%CI: 1.42, 3.23). The OR in
men were 5.91 (95%CI: 2.35, 14.85) and 2.88 (95%CI: 1.38, 6.01), adjusting for age and corresponding to
with and without capacitive barrier. The OR in women were 3.50 (95%CI: 1.86, 6.59) and 2.09 (95%CI:
1.20, 3.64) with and without capacitive barrier. AUCs for measurements with capacitive barrier were
40.90.
Conclusion: ClearView detected the presence or absence of cardiovascular disease independent of other
conditions.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cardiovascular diseases (CVD), including hypertension, cor-
onary artery disease (CAD), cardiomyopathy, heart failure, and
stroke are the greatest cause of mortality, with over 17.3 million
people dying annually [1],costing $863 billion in direct and in-
direct economic expenditures each year [2]. Cardiovascular disease
is a common complex disorder, which can be caused by a single
gene or multifactorial conditions resulting from interactions be-
tween environmental (modiﬁable) and inherited (immutable) risk
factors [3]. While signiﬁcant progress in understanding the de-
velopment of CVD has been discovered, the mechanisms of in-
dividual CVD susceptibility are still not clearly understood. A
considerable number of studies suggest that altered levels of oxi-
dative stress within the cardiovascular environment are criticalaccess article under the CC BY lice
. Rizzo),
diagnostics.com (J. Zhang).contributors in the development of cardiovascular disease [4]
while others suggest CVD is a multifactorial disorder that involves
several genetic determinants, including mitochondrial dysfunction
[5]. Mitochondrial dysfunction has been associated with a wide
range of cardiovascular disorders such as cardiomyopathy and
hypertension [6]. In this regard, studies are beginning to illustrate
that mitochondria not only appear susceptible to damage medi-
ated by increased oxidative stress but also play a signiﬁcant role in
the regulation of cardiovascular cell function [4]. Furthermore,
oxidative metabolism of the mitochondria via biophoton emission,
is linked to increased production of reactive oxygen species (ROS)
and overall oxidative stress. This has led to accumulating evidence
that a commonality among cardiovascular disease development
and cardiovascular disease risk factors is due to increased mi-
tochondrial damage and dysfunction [4] which can be measured
through biophotonic emission. In this manuscript we will in-
troduce the utilization of the Clearview System (ClearView), which
can detect cardiovascular disease through the measurement of
mitochondria dysfunction through biophoton emission.nse (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Mitochondrial dysfunction and oxidative stress in heart failure [21].
Fig. 2. Illustration of biophoton mechanism [22].
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Mitochondria, also referred to as the “powerhouses” of cells,
are responsible for creating over 90% of energy needed by the body
to sustain life and support growth [7]. Not only do they generate
energy in the form of ATP, but they also regulate numerous cellular
functions relevant to cell outcome, such as apoptosis, generation of
oxidative free radicals, and calcium homeostasis. Mitochondria are
a major source of reactive oxygen species (ROS). Oxidative stress
occurs when excess ROS are generated and cannot be adequately
countered by the antioxidant systems [8]. Oxidative stress has also
been associated with loss of cells in heart failure, cardiomyopathy,
and increased ROS associated with mitochondrial dysfunction in
heart failure [8], suggesting there is a strong afﬁliation between
CVD development, and mitochondrial damage and function [9]
(Fig. 1).
Several factors can increase the risk of CVD; however, there is
lack of clarity to whether the risk factors alter cellular function.
Studies have demonstrated that several CVD risk factors such as
hypercholesterolemia and age can alter mitochondrial damage and
function [10] by increasing mitochondrial oxidative stress. It has
also been thought that CVD risk factors may act on the cardio-
vasculature by inducing mitochondrial damage and dysfunction,
thus facilitating a premature aging process [11]. Various studies
are focused on identifying mitochondrial sources of ROS; however,
these are limited to in vitro studies and lack the ability to detect
possible disruption of cellular communication as a contributor.
Through oxidative metabolism of the mitochondria exhibited by
biophoton emissions, we will demonstrate the ClearView system's
capability of detecting and measuring cell-to-cell communication
in vivo.
1.2. Biophoton detection
Biophoton emission, the spontaneous emission of light (pho-
tons) emanating from all living systems including humans, is
biochemically distinct from bioluminescence, which is generally
visible and involves specialized enzymatic mechanisms. Although
biophoton emission is described to be less than 1000 photons
per second per cm and are not visible to the naked eye [12], recent
advances in photo-detection make it possible to analyze biophoton
emission. Biophoton emission is found in oxidative metabolism in
mitochondria, free radical reactions with biomolecules, proteins,
and DNA. Biophoton emission has been known to be related to the
generation of ROS, and therefore could be used as a tool for the
investigation of oxidative stress [13] (Fig. 2). Boveris and Cadenas
[14] were the ﬁrst to demonstrate the potential usefulness of
biophoton detection for non-invasive monitoring of oxidative
metabolism and oxidative damage in living tissue. Several studies
repeatedly illustrate that the intensity of photon emission changesin a state of disease [15] and that disease cells emit signiﬁcantly
more biophotons than healthy cells. It has also been shown that
changes in biophotonic activity are indicative of changes in mi-
tochondrial ATP energy production manifested in physiological
and pathological conditions [16]. Biophoton emission has also
been found to be an expression of cell-to-cell communication re-
ﬂective of the functional state of the living organism, and its
measurement can be used to assess this state [17]. Over decades of
research in this area, several studies have made progress in in-
vestigating human biophoton emission in both basic and applied
research. Clinically relevant in vivo human biophoton detection is
currently being studied; however, the numbers of studies and
human subjects have been limited. Although the use of biophoton
emission for diagnostic and treatment purposes is in its infancy,
we have demonstrated the ability to detect several components of
cardiovascular disease through biophoton emission as assessed by
the ClearView system.
1.3. ClearView system
The ClearView system is a non-invasive, electrophysiological
measurement tool that has the possibility to determine autonomic
response and physical response indicators by measuring the
electrophysiological signals associated with human body systems.
It has been scientiﬁcally proven that every cell in the body emits
more than 100,000 light impulses or photons per second. These
light emissions, otherwise known as biophotons, have been found
to be the steering mechanism behind all biochemical reactions.
Unlike other bio-impedance devices, such as the electro-
cardiogram (ECG) and the electroencephalogram (EEG), that
measures the electrophysiology of the heart and brain, the Clear-
View system measures electromagnetic energy at a smaller scale
through ampliﬁcation of biophotons. It has been demonstrated
that biophoton emission is strongest in the hands [18]. It has also
been demonstrated that if a disease is present, biophotonic im-
balances are emitted between left and right hands, suggesting
diagnostic potential [19]. The ClearView system taps into the
global electromagnetic holographic communication system via the
ﬁngertips. The ﬁngers are a highly reﬁned component of the per-
ipheral nervous system; therefore, due to the high energy ex-
penditures of the nerves throughout the body, they require higher
proportionate numbers of mitochondria. Through measuring mi-
tochondrial respiration via biophoton detection, the ClearView
system has the ability to quantify electrophysiological biophoton
activity as it relates to the metabolic function of forty-nine (49)
identiﬁed organ systems.
The ClearView system consists of a camera that lies under a
glass electrode. When a ﬁnger is placed on the glass electrode of
Fig. 3. (A) High frequency voltage impulse generating localized electromagnetic ﬁeld. (B) Energized ionized ﬁnger image as depicted by the ClearView system.
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glass and detects the patterns of biophotons emitted from the
body through the ﬁngers. The high voltage impulse generates a
localized electromagnetic ﬁeld around the ﬁnger thus exciting and
amplifying the biophotonic ﬁeld within the skin, tissue, and nerves
within the ﬁngertip. This combination leads to an excitation of the
local air molecules, forming room temperature plasma. The energy
of the plasma is released via the ionization of the local air mole-
cules, thus emitting photons within the ultraviolet and visible light
spectrum. The ionization is captured by the camera and the cap-
tured image is relayed into a computer system where the light
image is analyzed via the proprietary software to assess it for
speciﬁc patterns (Fig. 3). Algorithms built upon a large database of
data correlated with speciﬁc diseases and states of health create a
prioritizing scoring method to recognize electrophysiological ac-
tivity associated with speciﬁc organ systems and disease states. At
the completion of the ﬁnger scans, a ClearView summary score for
the cardiovascular system of the body, namely “cardiovascular
score”, is produced along with four summary scores for hepatic,
renal, respiratory, and gastrointestinal systems in the body. The
ClearView systemwas utilized in this study to determine if it could
detect and associate cardiovascular disease with the ClearView
cardiovascular score as compared to a medical practitioner's
diagnosis2. Methods
2.1. Subjects
We conducted a prospective, single center, non-randomized
trial of 353 patients who met eligibility criteria (NCT01476995).
Men and women aged 18–85 who presented with one of following
qualifying diagnoses of coronary artery disease (CAD), gastro-
intestinal disease, diabetes (type 1 or 2), asthma, COPD, acute or
renal failure, acute or chronic hepatitis, or cirrhosis and were a
patient of record at the Greater Baltimore Medical Center (GBMC)
were enrolled and labeled as the “diagnoses group”. Subjects were
only enrolled if they presented with at least one of the conﬁrmed
active medical diagnosis:
1. Cardiovascular system: coronary artery disease, left sided con-
gestive heart failure with ejection fraction o50%, valvular heart
disease, atrial ﬁbrillation, hypertension.
2. Gastrointestinal/endocrine: inﬂammatory bowel disease (in-
cluding Crohn's disease, ulcerative colitis, or diverticulitis),
peptic ulcer disease, IBS, cholecystitis, pancreatitis, malabsorp-
tion disorders (including Celiac Sprue), diabetes (Type 1 and
Type 2).
3. Respiratory: asthma, COPD, bronchitis, emphysema, or
pneumonia.4. Renal: pyelonephritis, acute renal failure, chronic renal failure
stages II–V.
5. Hepatic: viral hepatitis, alcoholic hepatitis, steatohepatitis,
cirrhosis.
The control group consisted of men and women aged 18–85
who were disease naïve (N¼64). All vulnerable subjects were
excluded. This study was conducted according to US and inter-
national standards of Good Clinical Practice (21 CFR part 812 and
International Conference on Harmonization guidelines), applicable
government regulations and Institutional research policies and
procedures, and adherence to the Declaration of Helsinki. All
qualifying subjects were consented properly (21 CFR part 50) and
medical history and self-reported questionnaires were collected.
Additionally, for all subjects enrolled in the qualifying diagnoses
groups, all tests and diagnoses from the past six months were
obtained from each subject's medical chart by the clinical co-
ordinator. Both groups were scanned with the ClearView scanner
by a masked research assistant. This study was ethnically diverse.
This study was approved by the local Institutional Review Board at
the Greater Baltimore Medical Center (IRB #10-033-05).
2.2. Blinding
This was a non-randomized study design. The researcher and
research assistant assigned to the study were masked to the pa-
tient's diagnoses and documentation. The research assistant in-
formed physicians and staff members that he/she must remain
blinded to the diagnoses of the patient but may coordinate with
physicians or staff members to schedule subjects for measure-
ment. Subjects were asked whether they would give their per-
mission for the clinical coordinator, who will be collecting medical
history information, to contact them directly for scheduling pur-
poses. Eligibility for the control group (healthy individuals iden-
tiﬁed from a similar population with respect to factors such as age
and geographic area) was identiﬁed by interviews or pre-screen-
ing medical charts, if available. In order to ensure consistency of
medical background for both the qualifying diagnoses group and
the control group, all efforts were made to standardize the medical
history data gathering between the two subject groups (diagnoses
group and control group).
2.3. Measurement procedures
Participation in the trial required approximately one hour of
each subject's time, including obtaining informed consent, an-
swering questions, and image capture. Measurement sessions with
the ClearView scanner took approximately ﬁfteen (15) minutes.
During measurement sessions, subjects were asked to place each
of their ten (10) ﬁngertips on the ClearView glass electrode, and an
image was captured through use of the ClearView software. All ten
Table 1
Cardiovascular diagnosis' as deﬁned by standard of care and physician diagnosis.
Cardiovascular disease
classiﬁcation
Cardiovascular
(N¼195)
Control
(N¼64)
Coronary Heart Disease 72 (36.92%) 0
Left-sided Congestive Heart Failure
w/ ejection fraction o50%
29 (14.87%) 0
Valvular heart disease 16 (8.21%) 0
Atrial ﬁbrillation (AF) 31 (15.90%) 0
Hypertension 158 (81.03%) 0
N.R. Rizzo et al. / Redox Biology 8 (2016) 11–1714(10) ﬁngers were measured twice; once with a capacitive barrier
and once without a capacitive barrier, for a total of twenty (20)
images. The capacitive barrier is designed to separate physical and
psychological factors of the images. If the device operator deemed
that an image was of poor quality (e.g., the subject rolled his or her
ﬁnger, ambient light entered the image), the image of that ﬁnger
was retaken. To assess the reproducibility and variability of the
measurements, a second measurement session was done 3–5 min
after the ﬁrst one was completed. Thus, each subject had a total of
four (4) ClearView measurements, two with and two without ca-
pacitive barriers. Each ﬁngertip measurement was about 0.5 s in
duration. The ﬁrst set of measurements was used for the primary
analysis endpoints.
2.4. Deﬁnition of cardiovascular disease
Subjects who were classiﬁed under cardiovascular disease
presented or were diagnosed by a medical practitioner at GBMC
with either coronary artery disease (N¼72), congestive heart
failure (N¼29), hypertension (N¼158), atrial ﬁbrillation (N¼31),
and/or valvular heart disease (N¼16). One hundred ninety-ﬁve
(195) subjects were diagnosed having at least one cardiovascular
disorder based on physical symptoms, risk factors, physical exam,
and results from procedures, blood work and diagnostics.
2.5. Statistical analyses
The ClearView system provides a score associated with the
cardiovascular system on a continuous scale from 0 to 5 re-
presenting the functionality of the system from good to poor. The
primary hypothesis of this study was there would be an associa-
tion of the ClearView cardiovascular score with the presence or
absence of cardiovascular disease in an active medical diagnosis,
quantiﬁed by an odds ratio. This trial had a planned sample size of
at least 360 subjects. With an expected odds ratio of 1.2, a two-
sided signiﬁcance level of α¼0.05, 360 subjects would yield at
least 95% power for each of the primary analyses. Sample size
calculations were conducted using SAS 9.4 PROC POWER (SAS
Institute, Cary NC).
Baseline characteristics, including age, sex, and other chronic
conditions, were compared between cardiovascular subjects and
controls. Logistic regression model was ﬁtted to examine the as-
sociation between the ClearView cardiovascular score and the
presence of cardiovascular disease adjusting for potential con-
founders, age, and diagnoses of chronic conditions related to liver,
kidney, respiratory system, and gastrointestinal/endocrine deﬁ-
ciency. The effect modiﬁcation by sex was examined using strati-
ﬁed analysis, although no effect modiﬁcations by the diagnoses of
liver, kidney, respiratory, and gastrointestinal disorders were
assumed.
In all models, odds ratios and areas under the receiver oper-
ating characteristic (ROC) curves (AUC) with 95% conﬁdence in-
tervals were summarized on measurements with and without
capacitive barrier. All analyses were conducted in SAS 9.4.3. Results
In total, 195 subjects had at least one cardiovascular diagnosis
and 64 were completely healthy subjects, giving a sample of 259
individuals for the analysis (Table 1). Among the 64 controls, 25
(39.06%) were men. Among the 195 subjects with cardiovascular
diagnosis, 113 (57.95%) were men. The mean age of cardiovascular
subjects was 64.22 (95%CI: 62.44, 65.99) and the mean age of
controls was 44.14 (95%CI: 40.73, 47.55). Table 2 summarized the
distribution of clinical comorbidities of the 195 subjects with acardiovascular diagnosis and ClearView system scores in the
sample.
As shown in Table 1, the majority of subjects with cardiovas-
cular diagnosis had hypertension, followed by Coronary Heart
Disease. As illustrated in Table 2, almost half of the subjects with
cardiovascular problems had gastrointestinal disorders diagnosed,
among which 74 were diabetics. The proportion of respiratory
diagnosis in the 195 subjects with cardiovascular problem was
37.45%, the majority of which were asthma or COPD. Chronic renal
failure accounts for the highest proportion of renal problems
among subjects with cardiovascular diagnosis. The major liver
disorder among the same group was viral hepatitis.
In Table 3, the overall odds ratios of the cardiovascular score to
predict the overall diagnosis of cardiovascular disease were 4.03
(95%CI: 2.71, 6.00) and 2.84 (95%CI: 1.98, 4.09) for measures
completed with and without the capacitive barrier, respectively.
This indicated a substantial increase in the likelihood of an elec-
trophysiological disturbance within the cardiovascular system for
each unit increase of the ClearView score. For each cardiovascular
disorder, the odds ratios ranged from 2.39 to 5.43 for measure-
ments with capacitive barrier and almost all AUCs were greater
than 0.80 except for valvular heart disease. In the absence of the
capacitive barrier, the odds ratios ranged between 2.84 and 4.44
and all AUCs were greater than 0.70.
Potential confounding effects by age and diagnosis of other co-
morbidities were summarized in Table 4. The odds ratios adjusted
by age did not change much compared to those in Table 3, al-
though AUCs increased substantially by adding age in the logistic
regression model. Adding other diagnosis of chronic diseases to
the logistic regression model, however, did not alter odds ratios or
AUCs much when age had been adjusted. This indicated that the
diagnosis of other chronic diseases was not a confounder for the
association between ClearView score and the diagnosis of cardio-
vascular disease. In addition, the diagnoses of other chronic dis-
eases were not signiﬁcant predictors for cardiovascular disease
when ClearView score and age were in the model. In all adjusted
models, odds ratios and AUCs for measurements with capacitive
barrier were consistently higher than those without capacitive
barrier, although the differences were relatively small.
The odds ratios by sex were higher than the crude odds ratio,
indicating an effect modiﬁcation by sex, when capacitive barriers
were used in ﬁnger scans. In contrast, the odds ratios by sex for
measurements without capacitive barrier did not differ much from
the unstratiﬁed odds ratio. The odds ratios and AUCs for mea-
surements with capacitive barrier were higher than those without
capacitive barrier.4. Discussion
In this project, the ability of the ClearView system to detect
presence or absence of disease demonstrated strong association
with the diagnosis of cardiovascular disease, adjusting for age yet
independent of other comorbidities. In other words, the high
Table 2
Sample characteristics comparing cardiovascular subjects with comorbities and control (N¼259).
Diagnosis of comorbidities Cardiovascular (N¼195) Control (N¼64)
Gastrointestinal/endocrine diagnosis Yes 97 (49.74%) 0
No 98 (50.26%) 64 (100%)
Gastrointestinal/endocrine diagnosis Inﬂammatory bowel disease (IBD) 1 (0.51%) 0
Crohn's disease 5 (2.56%) 0
Ulcerative colitis 4 (2.05%) 0
Diverticulitis 8 (4.10%) 0
Peptic ulcer disease 5 (2.56%) 0
Irritable bowel syndrome 5 (2.56%) 0
Cholecystitis 2 (1.03%) 0
Malabsorption disorders 2 (1.03%) 0
Pancreatitis 7 (3.59%) 0
Diabetes 74 (37.95%) 0
Cardiovascular diagnosis Yes 195 (100%) 0
No 0 (0%) 64 (100%)
Cardiovascular Coronary Heart Disease 72 (36.92%) 0
Left-sided Congestive Heart Failure w/ejection fraction
o50%
29 (14.87%) 0
Valvular heart disease 16 (8.21%) 0
Atrial ﬁbrillation (AF) 31 (15.90%) 0
Hypertension 158 (81.03%) 0
Kidney diagnosis Yes 52 (26.67%) 0
No 143 (73.33%) 64 (100%)
Kidney Pyelonephritis 4 (2.05%) 0
Acute renal failure 18 (9.23%) 0
Chronic renal failure stage II–IV 41 (21.03%) 0
Liver diagnosis Yes 21 (10.77%) 0
No 174 (89.23%) 64 (100%)
Liver Viral hepatitis 17 (8.72%) 0
Alcoholic hepatitis 2 (1.03%) 0
Steatohepatitis 2 (1.03%) 0
Cirrhosis 4 (2.05%) 0
Respiratory diagnosis Yes 73 (37.45%) 0
No 122 (62.56%) 64 (100%)
Respiratory Asthma 30 (15.38%) 0
Chronic obstructive pulmonary disease (COPD) 37 (18.97%) 0
Bronchitis 8 (4.10%) 0
Emphysema 6 (3.08%) 0
Pneumonia 16 (8.21%) 0
Autonomic (ClearView system scores) Gastrointestinal score Mean (s.d.) 2.51 (0.61) 2.23 (0.43)
Cardiovascular score Mean (s.d.) 3.58 (0.96) 2.72 (0.75)
Respiratory score Mean (s.d.) 2.15 (0.68) 1.61 (0.44)
Liver score Mean (s.d.) 0.61 (0.11) 0.60 (0.17)
Kidney score Mean (s.d.) 1.18 (0.68) 0.82 (0.46)
Physical (ClearView system scores) Gastrointestinal score Mean (s.d.) 2.55 (0.63) 1.93 (0.42)
Cardiovascular score Mean (s.d.) 3.62 (0.88) 2.45 (0.88)
Respiratory score Mean (s.d.) 2.23 (0.79) 1.34 (0.48)
Liver score Mean (s.d.) 0.65 (0.27) 0.46 (0.20)
Kidney score Mean (s.d.) 1.22 (0.62) 0.60 (0.31)
N.R. Rizzo et al. / Redox Biology 8 (2016) 11–17 15discrimination ability on disease and healthy subjects found in the
ClearView system's indication of presence or absence of disease
did not depend on the presence of other comorbidities. The pre-
sence of age, however, contributed signiﬁcantly to the prediction
of cardiovascular disease, which was consistent with results found
in the literature [20].
Limitations included sample size. Due to sample size con-
straints, the association between the ClearView system and each
cardiovascular condition was not investigated when assessing the
confounding effects of other chronic conditions. Such associations
can be examined in further studies of the ClearView technology.
Similarly, the confounding effects of other chronic conditions were
assessed as overall diagnoses.5. Conclusions
This study demonstrated the ClearView system's ability to de-
tect the presence or absence of cardiovascular disease. It has also
been proven to be a quantitative assessment tool consistent withknown behavior of biophoton research done in-vitro. Study ﬁnd-
ings were consistent across several other diagnosis groups, for
measurements both with and without the capacitive barrier (re-
sults will be reported in future publications). The device is ap-
plicable to a broad spectrum of individuals, as reﬂected by this
study's population. This study incorporated a variety of diagnoses,
including long-term disease such as non-communicable diseases
(e.g., CVD), as well as subjects who were experiencing more im-
mediate medical issues and required in-patient care. Furthermore,
with subjects covering an age range from 18 to 85 years, and an
almost equal distribution of men and women, the study popula-
tion reﬂected the wide applicability of the ClearView system. Be-
sides determining the ability to detect and diagnose different
components of cardiovascular disease, ClearView also demon-
strated safety. No serious adverse events were reported or oc-
curred during the study. Out of 353 subjects, each completing
multiple measurements on each of their 10 ﬁngers, only three
reports of tingling at the ﬁngertips (an anticipated event) were
reported. The multiple measurements per subject are indicative of
the ability to use the device repeatedly without negative effects.
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during the course of the study.
Our ﬁndings suggest that an objective, non-invasive measure-
ment tool could be implemented as a universal screening and
treatment efﬁcacy device for CVD. Typically, age, family history or
risk factors that increase an individual's risk of developing cardi-
ovascular disease will determine who should be assessed for car-
diovascular health risk. Even if individuals may have a low risk of
developing CVD, literature indicates there is high likelihood of
developing a variety of cardiovascular issues of varying severity,
and therefore may not be properly assessed, diagnosed, or treated.
By screening patients early, CVD can be prevented and treated
properly. Implementation of the ClearView system could not only
consistently identify patients that could be at risk early, but could
effectively reduce the national prevalence of disease as well as
decrease the mortality rate associated with CVD. Through early
detection, CVD could be prevented or treated properly which
would not only ameliorate the risk factors associated with the
disease, but could cut medical expenditures and all around health
care costs. In today's current cardiovascular disease diagnosis
model, patients may undergo a myriad of tests depending on
symptomology and severity of early results. Various tests are uti-
lized to make a true diagnosis and can take weeks even months to
complete all appropriate testing and even longer to make a deﬁ-
nitive diagnosis. Early screening usually involves blood tests and
an electrocardiogram (ECG) and based on these results, further
testing may or may not be required. Typically echocardiograms,
stress tests, cardiac computerized tomography (CT) scan, magnetic
resonance imaging (MRI), coronary angiogram and even a myo-
cardial biopsy may be ordered and utilized to rule out or to make
an appropriate speciﬁc cardiovascular related diagnosis. Although
testing for cardiovascular disease has been known to be effective
and treatment depending on diagnosis can be highly efﬁcacious, a
more effective, less time consuming, more integrated, less invasive
model needs to be implemented. Changes in medical care ex-
penditures through early detection and diagnosis will be beneﬁcial
for not only patients, but for health insurers, employers, and
health care administration. The value of having such an objective
screening tool could also assist a medical practitioner in proper
and immediate treatment. Providing a physician with an in-
tegrated complex aggregate of medical information that can be
utilized in real time, will not only allow a provider to make a fully
informed decision based on early results, but can optimize health
care and assist as an efﬁcient approach to next steps in the stan-
dard of care process. Although the ClearView system does not
dictate the standard of care process that needs to be followed, by
utilizing such an integrative device can reduce the time and
amount of tests needed to make an appropriate diagnosis, which
in turn can not only cut medical costs, but can also allow patients
to be diagnosed in a safe, timely, non-invasive fashion.Funding
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Table 4
Associations between ClearView cardiovascular scores and diagnosis of cardiovascular disease, stratiﬁed by sex, adjusted for age, and diagnosis of hepatic, renal, gastro-
intestinal, and respiratory disorders.
With capacitive barrier Without capacitive barrier
ClearView response Potential con-founders Cardio-vascular Diagnosis N Control N Odds ratio (95% CI) AUC (95%CI) Odds ratio (95% CI) AUC (95%CI)
Cardio-vascular score Age 195 64 3.44*** (2.13, 5.55) 0.91 (0.87, 0.95) 2.15** (1.42, 3.23) 0.88 (0.84, 0.93)
Cardio-vascular score Age, hepatic 195 64 3.69*** (2.22, 6.14) 0.93 (0.89, 0.96) 2.27*** (1.46, 3.51) 0.90 (0.86, 0.94)
Age, renal 195 64 2.89*** (1.78, 4.71) 0.92 (0.89, 0.96) 1.99** (1.29, 3.09) 0.91 (0.87, 0.94)
Age, gastro-intestinal 195 64 3.57*** (2.02, 6.28) 0.96 (0.93, 0.98) 2.93*** (1.69, 5.06) 0.95 (0.92, 0.97)
Age, respiratory 195 64 2.64*** (1.62, 4.28) 0.93 (0.90, 0.96) 1.80* (1.12, 2.87) 0.92 (0.89, 0.95)
Cardio-vascular scorea Male 113 25 5.91*** (2.35, 14.85) 0.93 (0.88, 0.99) 2.88** (1.38, 6.01) 0.92 (0.86, 0.97)
Female 82 39 3.50*** (1.86, 6.59) 0.90 (0.85, 0.96) 2.09** (1.20, 3.64) 0.86 (0.79, 0.92)
*** p-valueo0.001.
** p-valueo0.01.
* p-valueo0.05.
a Adjust for age.
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